Sign in Subscribe
Brain injuries

Breakthrough in Brain Injury Research: Perampanel Shows Significant Advantage in Preventing Acute Symptomatic Seizures

Strategic Insights

— 1 min read

Researchers from Osaka Medical and Pharmaceutical University have published a study in Frontiers in Neurology comparing the effectiveness of perampanel and levetiracetam in preventing acute symptomatic seizures (ASS) following moderate to severe traumatic brain injury (TBI). The study found that perampanel demonstrated a significant advantage over levetiracetam in preventing ASS, with a lower incidence rate of 7.7% compared to 42.1% in the levetiracetam group.

Key Takeaways:

  • The study included 32 patients with moderate to severe TBI who received either levetiracetam (n = 19) or perampanel (n = 13) as prophylactic anti-seizure therapy.
  • The primary outcome was the incidence of ASS within 7 days post-injury, with significant differences found between the perampanel and levetiracetam groups.
  • Secondary outcomes included post-traumatic epilepsy (PTE) development, psychiatric adverse events (PAEs), and functional outcomes assessed by the Glasgow Outcome Scale-Extended (GOS-E) at 3 months.
  • There were no significant differences in PTE development, PAEs, or favorable GOS-E scores between the perampanel and levetiracetam groups.
  • Perampanel demonstrated a comparable psychiatric safety profile and functional outcomes to levetiracetam, making it a promising therapeutic option for acute seizure prophylaxis in TBI patients.

Statistics:

  • 7.7% incidence rate of ASS in the perampanel group compared to 42.1% in the levetiracetam group (OR 0.115, p = 0.050).
  • 23.1% incidence rate of PTE in both groups (OR 0.84, p 0.99).
  • 23.1% incidence rate of PAEs in both groups (p 0.99).
  • 38.5% favorable GOS-E scores in the perampanel group compared to 26.3% in the levetiracetam group (p 0.707).

Sources:

  • Frontiers in Neurology (http://frontiersin.org/neurology)
  • Acute symptomatic seizure prevention with perampanel in moderate and severe traumatic brain injury: a retrospective comparison with levetiracetam. Frontiers in Neurology, 2025,16. (https://doi-org.sdpl.idm.oclc.org/10.3389/fneur.2025.1665997)

Read more